ONLINE APPENDIX

**Figure 1.** Effects of single injections of insulin glargine (0, 0.5, 1.0, 1.5 and 2.0 u/kg) on plasma glucagon, NEFA and β-hydroxybutyrate levels in overnight fasted type 2 DM. Plasma glucagon levels are suppressed (p<0.05) by all doses of glargine as compared to placebo. Blood NEFA and plasma β-hydroxybutyrate levels are also suppressed (p<0.05) following insulin glargine doses as compared to placebo.
### Appendix Table 1.

#### Demographics and Treatment of Study Participants

| Age (yrs) | Sex       | BMI kgM² | HBA1C % | Diabetes Durations (yrs) |
|-----------|-----------|----------|---------|--------------------------|
| 50 ± 3    | 10 M / 10 F | 36 ± 2   | 8.3 ± 0.6 | 8 ± 1                    |

| Fat %    | Potassium mmol/L | Creatinine mg/dl | SGOT U/L | SGPT U/L |
|----------|------------------|------------------|----------|----------|
| 34 ± 2   | 4.0 ± 0.09       | 0.9 ± 0.05       | 27 ± 3   | 26 ± 3   |

#### Treatment

| Treatment                                                                 | N     | Insulin Dose (units) |
|--------------------------------------------------------------------------|-------|----------------------|
| Metformin                                                                | 1     |                      |
| Metformin plus Sulfonylurea                                              | 3     |                      |
| Metformin plus Exenatide                                                | 2     |                      |
| Metformin, Glargine, Exenatide                                          | 2     | 20, 48               |
| Metformin, Exenatide, NovoLog / Novolin N / NovoLog mix                 | 2     | 45, 60               |
| Metformin, Humulog, Glargine                                            | 7     | 11 - 70              |
| Metformin, Detemir, Sulfonylurea                                         | 1     | 70                   |
| Metformin, Sulfonylurea, Glargine                                       | 2     | 20, 30               |